Letrozol Stada

Letrozole, the active ingredient in Letrozol Stada, is an aromatase inhibitor presented as a tablet for oral use. It works by reducing estrogen production and is indicated for hormone‑positive breast cancer in postmenopausal women, helping to slow tumor growth and improve clinical outcomes.

GNH USA supplies Letrozol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letrozol Stada is an aromatase inhibitor used in the management of hormone‑driven breast cancer.

Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen‑driven tumor proliferation. Adjuvant therapy for early‑stage disease: lowers risk of recurrence after surgery. Metastatic breast cancer in postmenopausal women: helps control disease progression.

Letrozol Stada may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes. - Bone fracture: increased risk of osteoporosis‑related breaks. - Pulmonary embolism: sudden shortness of breath or chest pain. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Elevated cholesterol: changes in lipid profile.

Before initiating Letrozol Stada, clinicians should consider several safety measures.

Monitor bone mineral density: assess risk of osteoporosis and consider supplementation. Assess liver function: check enzymes prior to therapy and periodically during treatment. Evaluate cardiovascular risk: review history of thromboembolic events. Avoid use in pregnancy: Letrozole is contraindicated and teratogenic. Store at ambient temperature (below 25 °C): keep in the original pack, protect from moisture.

Letrozol Stada can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Estrogen‑containing hormone replacement therapy: reduces Letrozole efficacy. - Strong CYP2A6 inhibitors (e.g., ketoconazole): may increase Letrozole plasma levels. - Potent CYP3A4 inducers (e.g., rifampin): may lower Letrozole concentrations.

Moderate Interactions (Monitor Closely): - Tamoxifen: potential antagonistic effect on estrogen pathways. - Warfarin: Letrozole may alter INR values. - Selective serotonin reuptake inhibitors (SSRIs): possible effect on drug metabolism.